FDA Revises 'Disruptive' Generics Communications Policies
This article was originally published in Scrip
Executive Summary
The FDA on Aug. 18 unveiled a newly revised manual of policies and procedures (MAPP) intended to improve the communications between regulators reviewing abbreviated new drug applications (ANDAs) and the companies that have submitted them.